Value Research Rating

2 star

Quality Score fund-quick-summary-circle

Quality Score0/0

Growth Score fund-quick-summary-circle

Growth Score0/0

Valuation Score fund-quick-summary-circle

Valuation Score0/0

Momentum Score fund-quick-summary-circle

Momentum Score0/0

Glenmark Pharmaceuticals Ltd. Share Price

High:loading Low:loading Return: loading

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...

Stock Range

Today’s Range
Low: 1,310.90 High: 1,437.35
52 Week Range
Low: 771.00 High: 1,830.95
Liquidityliquidity High
Low Moderate High

Fundamentals

  • Market capMarket cap information

    ₹37,287 Cr

  • P/E RatioP/E Ratio information

    --

  • P/B RatioP/B Ratio information

    4.24

  • Industry P/EIndustry P/E information

    37.17

  • Debt to EquityDebt to Equity information

    0.13

  • ROEROE information

    -21.18 %

  • ROCEROCE information

    4.88 %

  • Div. YieldDiv. Yield information

    0.19 %

  • Book ValueBook Value information

    311.63

  • EPSEPS information

    -43.43

10 Years Aggregate

CFO

₹8,448.41 Cr

EBITDA

₹16,822.44 Cr

Net Profit

₹4,609.43 Cr

Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Glenmark Pharmaceuticals
-17.78 -11.61 -14.05 58.98 39.30 32.20 5.61
BSE Healthcare
-11.69 -6.28 -6.00 12.99 17.86 22.52 9.66
BSE Mid Cap
-14.35 -6.28 -9.92 2.49 17.89 20.27 13.97
As on 14-Feb-2025
2024
2023
2022
2021
2020
2019
2018
Glenmark Pharmaceuticals
88.06 101.33 -19.75 5.16 42.75 -49.80 16.26
BSE Mid Cap
25.84 45.53 1.38 39.18 19.87 -3.05 -13.31
BSE Healthcare
43.09 36.97 -12.10 20.87 61.45 -3.55 -5.89

Essential Checks View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials Detailed View

loading...

*All values are in (₹ Cr)

loading...

*All values are in (₹ Cr)

loading...

*All values are in (₹ Cr)

Key Ratios view all

loading...

loading...

loading...

3Y Avg -- 5Y Avg -- TTM --

loading...
P/E Ratio

--

--Min --Median --Max

loading...
P/B Ratio

--

--Min --Median --Max

loading...
Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peer view all

Company
Price (₹) Market Cap (₹ Cr) P/E Ratio ROE
546.20 29,472.84 147.17 4.86
184.90 24,499.83 629.82 0.67
1,089.65 27,701.76 99.21 13.86
690.35 27,803.23 55.44 11.04

Shareholding Pattern Detailed Holdings

loading...
BLAHBLAH

News & Analysis All News

About The Company

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company provides branded and generic...  formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific antibody, which is in Phase 1 clinical trial for oncology; GRC 39815, a retinoid-related orphan receptor gamma t inverse agonist, which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor, which is in Phase 1 clinical trial for the treatment of solid tumors. Its pipeline also comprises ISB 1342, CD38 X CD3 bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 immune cell engager, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 880, a IL-1RAP antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a OX40 antagonist, which is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. Glenmark Pharmaceuticals Limited was incorporated in 1977 and is based in Mumbai, India.  Read more

  • Incorporated

    1977

  • Chairman

    Glenn Saldanha

  • Managing Director

    Glenn Saldanha

  • Group

    Glenmark

  • Headquarters

    Mumbai, Maharashtra

  • Website

    www.glenmarkpharma.com

Edit peer-selector-edit
loading...
loading...
loading...
loading...

Quarterly Updates

FAQs for Glenmark Pharmaceuticals Ltd.

The total asset value of Glenmark Pharmaceuticals Ltd stood at ₹ 15,235 Cr as on 31-Dec-24

The share price of Glenmark Pharmaceuticals Ltd is ₹1,323.05 (NSE) and ₹1,321.35 (BSE) as of 14-Feb-2025 IST. Glenmark Pharmaceuticals Ltd has given a return of 39.3% in the last 3 years.

Glenmark Pharmaceuticals Ltd has a market capitalisation of ₹ 37,287 Cr as on 14-Feb-2025. As per Value Research classification, it is a Mid Cap company.

The P/B ratio of Glenmark Pharmaceuticals Ltd is 4.24 times as on 14-Feb-2025, a 22% premium to its peers’ median range of 3.48 times.

Since, TTM earnings of Glenmark Pharmaceuticals Ltd is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Glenmark Pharmaceuticals Ltd and enter the required number of quantities and click on buy to purchase the shares of Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific antibody, which is in Phase 1 clinical trial for oncology; GRC 39815, a retinoid-related orphan receptor gamma t inverse agonist, which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor, which is in Phase 1 clinical trial for the treatment of solid tumors. Its pipeline also comprises ISB 1342, CD38 X CD3 bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 immune cell engager, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 880, a IL-1RAP antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a OX40 antagonist, which is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. Glenmark Pharmaceuticals Limited was incorporated in 1977 and is based in Mumbai, India.

The promoter of Glenmark Pharmaceuticals Ltd is SALDANHA FAMILY TRUST. SALDANHA FAMILY TRUST owns 45.45 per cent of the total equity. The chairman of the company is Glenn Saldanha , and the managing director is Glenn Saldanha..

There is no promoter pledging in Glenmark Pharmaceuticals Ltd.

Some of the close peers are:

Company Market Cap(₹ Cr)
29,473
27,803
27,702
24,500
Glenmark Pharmaceuticals Ltd. Ratios
Return on equity(%)
-15.04
Operating margin(%)
13.58
Net Margin(%)
-1.4
Dividend yield(%)
0.19

No, TTM profit after tax of Glenmark Pharmaceuticals Ltd was ₹-176 Cr.